证券代码：600976 证券简称：健民集团 公告编号：2023-034 健民药业集团股份有限公司 关于《2022 年限制性股票激励计划》所涉限制性股票 首次解锁上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 184,800 股。 本次股票上市流通总数为 184,800 股。 本次股票上市流通日期为 2023 年 9 月 21 日。 （一）《2022 年激励计划》主要内容 公司《2022 年激励计划》股份来源为从二级市场回购的公司 A 股普通股股 票，采用限制性股票的激励方式，向何勤董事长等 6 名激励对象授予的限制性股票 数量为 369,600 股，占公司股本总额 153,398,600 股的 0.24%，无预留股份。 《2022 年激励计划》所涉限制性股票的授予价格为 20.58 元/股，授予日为 2022 年 9 月 5 日。《2022 年激励计划》公司层面的业绩考核以 2021 年归属于上市公司 股东的净利润 32,473.6 ...

公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于 2023 年 9 月 12 日发出召开第十届董事会第十五次 会议的通知，并于 2023 年 9 月 15 日以通讯方式召开本次会议，会议应参与表决的董 事 9 人,实际参与表决的董事 9 人，符合《公司法》和《公司章程》的规定。经到会董 事充分讨论，审议通过如下议案： 1、关于《2022 年限制性股票激励计划》所涉限制性股票首次解锁的议案 同意：7 票 弃权：0 票 反对：0 票 回避：2 票 何勤董事长、汪俊董事为本议案的受益人，回避表决。 公司《2022 年限制性股票激励计划》于 2023 年 9 月 16 日进入解锁期，首个解锁 期解锁条件成就，可解锁股份 184,800 股将于 2023 年 9 月 21 日解锁并上市流通，详 见上海证券交易所网站（http://www.sse.com.cn）及指定媒体公司披露的《健民药业 集团股份有限公司关于<2022 年限制性股票激励计划>所涉限制性股票首次解锁上市的 公告》。 2、关于调整董事会专门委 ...

关于公司《2022 年限制性股票激励计划》首次解锁激励 对象名单的核查意见 （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； 健民药业集团股份有限公司监事会 健民药业集团股份有限公司（以下简称"公司"）监事会根据《公司法》、《证 券法》《上市公司股权激励管理办法》（以下简称：管理办法）等有关法律、法规 和规范性文件以及公司《2022 年限制性股票激励计划》（以下简称：激励计划） 和《公司章程》的有关规定，监事会对公司《激励计划》首次解锁激励对象名单 进行审核，发表如下意见： 1、公司《激励计划》首次解锁激励对象不存在《管理办法》规定的不得成 为激励对象下列情形： （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； 3、公司不存在法律、法规和规范性文件规定的不得实施股权激励的情形； 公司未发生《激励计划》）中规定的不得解除限售的情形，经董事会确认公司层 面的业绩考核指标已达成。 综上，监事会认为公司《激励计划》首次解锁所涉激励 ...

证券代码：600976 证券简称：健民集团 公告编号：2023-033 健民药业集团股份有限公司 特此公告。 健民药业集团股份有限公司 第十届监事会第七次会议决议公告 监 事 会 二○二三年九月十六日 同意：5 票 弃权：0 票 反对：0 票 监事会对《2022 年限制性股票激励计划》（以下简称《激励计划》）首次解锁所 涉激励对象进行核查，并发表了相关核查意见，监事会认为本次解锁的 6 名激励对 象符合《激励计划》规定的解锁条件，同意解锁相关事宜，详见上海证券交易所网 站(www.sse.com.cn)与本公告一起披露的《健民药业集团股份有限公司监事会关于 〈2022 年限制性股票激励计划〉首次解锁激励对象名单的核查意见》及《健民药业 集团股份有限公司关于<2022 年限制性股票激励计划>所涉限制性股票首次解锁上 市的公告》。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于 2023 年 9 月 12 日发出召开第十届监事会第七次 会议的通知，并于 2023 年 9 月 15 日以通讯方式召开本 ...

湖北得伟君尚律师事务所 关于健民药业集团股份有限公司 2022 年限制性股票激励计划 首次解锁期解锁条件成就的 法律意见书 二○二三年九月十五日 湖北得伟君尚律师事务所 地址：武汉市江汉区建设大道 588 号卓尔国际中心 20 楼、21 楼 电话：（86 27 8562 0999） 电子邮箱：dewell@dewellcn.com 邮政编码：430024 湖北得伟君尚律师事务所 关于健民药业集团股份有限公司 2022 年限制性股票激励计划 首次解锁期解锁条件成就的 法律意见书 致：健民药业集团股份有限公司 湖北得伟君尚律师事务所（以下称"本所"）接受健民药业集团 股份有限公司（以下称"健民集团"或"公司"）委托，作为公司《2022 年限制性股票激励计划》（以下简称《激励计划》）的专项法律顾问， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人 民共和国证券法》（以下简称《证券法》）、《上市公司股权激励管 理办法》（以下简称《管理办法》）等法律、行政法规、部门规章及 规范性文件（以下简称法律法规）和《健民药业集团股份有限公司章 程》（以下简称《公司章程》）的有关规定，就公司本次限制性股票 激励计划首 ...

证券代码：600976 证券简称：健民集团 公告编号：2023-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 经健民药业集团股份有限公司（以下简称：公司）2021 年第五次临时股东大 会批准，公司作为有限合伙人与关联方杭州华方创量投资管理有限公司（以下简 称：华方创量）、昆药集团股份有限公司等共同参与关联方杭州华方和昂投资管 理合伙企业（有限合伙）（以下简称：华方和昂基金）基金份额的认购，其中公 司以自有资金出资 5,000 万元，占华方和昂基金 49.505%的基金份额，详见公司 于 2021 年 12 月 15 日披露的《关于对外投资暨关联交易的公告》。 二、相关进展 近日，公司收到华方和昂基金管理人相关通知，根据相关法律法规的要求， 合伙企业华方和昂基金已全部完成实缴出资，实际募集资金人民币 1.01 亿元。 各合伙人实缴出资情况如下： | 投资人名称 | 类型 | 出资 | 实缴出资额（万元） | 实缴比例 | | --- | --- | --- | --- | --- | | | | 方 ...

证券代码：600976 证券简称：健民集团 公告编号：2023-030 健民药业集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 08 月 16 日(星期三)下午 15:00-16:00 会议召开地点：上证路演中心（网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 09 日(星期三)至 08 月 15 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir.jmjt@whjm.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间： ...

Financial Performance - The company's operating revenue for 2022 was RMB 364,080.05 million, representing a 10.35% increase compared to RMB 329,942.97 million in 2021[18]. - The net profit attributable to shareholders of the listed company reached RMB 40,756.91 million, a 33.52% increase from RMB 30,525.82 million in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 37,391.08 million, up 24.42% from RMB 30,053.38 million in 2021[18]. - The net cash flow from operating activities was RMB 21,586.53 million, a decrease of 12.93% compared to RMB 24,792.11 million in 2021[18]. - As of the end of 2022, the total assets amounted to RMB 343,765.93 million, reflecting a 20.36% increase from RMB 285,607.70 million at the end of 2021[18]. - The net assets attributable to shareholders of the listed company were RMB 186,286.16 million, which is a 25.79% increase from RMB 148,087.77 million in the previous year[18]. - The basic earnings per share (EPS) increased to RMB 2.68, up 33.33% from RMB 2.01 in 2021[19]. - The weighted average return on equity rose to 25.27%, an increase of 2.26 percentage points from 2021[19]. - The company reported a significant increase in pharmaceutical industrial revenue, which grew by 11.73% year-on-year[29]. - The company's pharmaceutical industrial revenue was 1.88 billion CNY, up 11.73% year-on-year, while pharmaceutical commercial revenue was 1.72 billion CNY, increasing by 8.52%[63]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 10 per 10 shares, totaling RMB 153,398,600 to all shareholders[4]. - In 2022, the company distributed cash dividends of 123,341,374 RMB, which accounted for 37.79% of the net profit attributable to shareholders[173]. - The total cash distribution, including share buybacks, amounted to 161,673,912.26 RMB, representing 49.56% of the net profit attributable to shareholders[174]. - The company has implemented a cash dividend policy, distributing a total of 630 million RMB in cash dividends over the past 14 years, reflecting a commitment to shareholder returns[172]. Risk Management - The company has not reported any significant risks that could materially affect its operations during the reporting period[6]. - The company emphasizes the importance of risk management in its operations, addressing various risks including industry policy, raw material, market competition, and R&D risks[6]. - The company faces risks from policy changes in the heavily regulated pharmaceutical industry, which could impact its operations[134]. - The company is actively working to diversify its product structure to mitigate risks associated with raw material price fluctuations[135]. - In 2022, the company faced risks related to raw material supply due to market demand and environmental factors, leading to an increase in traditional Chinese medicine material prices[136]. Research and Development - The company launched 26 new drug R&D projects in 2022, including 3 new pediatric formulations and received 1 clinical trial approval[35]. - The company has 40 ongoing research projects, including 26 new drug development projects and 8 secondary development projects[105]. - The total R&D investment for the year was RMB 72.66 million, with RMB 71.99 million classified as expense and RMB 0.68 million as capitalized[106]. - The company is focusing on the development of TCM new drugs, with ongoing projects including a new type of TCM granule and a pediatric cough syrup[52]. - The company is actively pursuing patent protections for its innovative drug formulations and preparation methods[100]. Market Expansion and Strategy - The company is focusing on innovation and quality as key drivers for future growth amidst a challenging market environment[29]. - The company plans to expand its market presence by opening a second TCM clinic in Hankou in March 2023[37]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 15% market share within the next three years[148]. - Strategic acquisitions are being considered to bolster the company's portfolio and enhance operational capabilities[148]. - The company is expanding its market share in hospitals and retail sectors while accelerating brand development and innovation in health products[137]. Corporate Governance - The company held four shareholder meetings in 2022, reviewing 23 proposals, ensuring compliance with legal and regulatory requirements[140]. - The board of directors convened 12 meetings in 2022, reviewing 57 proposals, and ensuring timely decision-making on significant matters[141]. - The audit committee held six meetings in 2022 to oversee financial reporting and compliance, enhancing the company's internal control[141]. - The supervisory board conducted eight meetings in 2022, focusing on compliance and risk management to safeguard the company's operations[143]. - The company has established strict insider information management protocols, ensuring no insider trading incidents occurred during the reporting period[143]. Environmental Responsibility - The company has invested 5.6 million CNY in environmental protection during the reporting period[186]. - The total emissions of key pollutants from the subsidiary were within the permitted limits, with COD emissions at 22.2 tons per year[189]. - The company has achieved compliance with environmental standards, with all monitored pollutants meeting regulatory limits[189]. - The company has established a comprehensive sewage treatment plant with a daily processing capacity of 800 tons, operating 24 hours a day[191]. - The company has implemented carbon reduction measures despite not being included in the national carbon market quota management list[199]. Employee Development - The company has established a comprehensive employee training system, conducting an MBA training program for 72 personnel in 2022[171]. - The company has committed to continuous talent development, focusing on cultivating high-level management talent through various training programs[171]. - The company has a performance-based salary system, adjusting salaries annually based on individual performance and company operating conditions[170]. - The company has initiated a stock incentive plan, granting 369,600 restricted shares to eligible employees in 2022[178]. - The workforce includes 165 R&D personnel, making up 21.8% of the total staff, indicating a strong focus on innovation[83].

证券代码：600976 证券简称：健民集团 公告编号：2023-003 健民药业集团股份有限公司 关于召开 2022 年度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 09 日(星期四)至 03 月 15 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir.jmjt@whjm.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 健民药业集团股份有限公司（以下简称"公司"）将于 2023 年 03 月 15 日发 布公司 2022 年年度报告及其相关公告，为便于广大投资者更全面深入地了解公 司 2022 年年度经营成果、财务状况，公司计划于 2023 年 03 月 16 日 ...

Financial Performance - The company's operating revenue for 2021 was RMB 3,278,183,640.34, representing a year-on-year increase of 33.48%[24]. - The net profit attributable to shareholders for 2021 was RMB 324,736,841.19, a significant increase of 119.73% compared to the previous year[24]. - The net cash flow from operating activities increased by 106.46% to RMB 259,183,455.41, driven by growth in sales scale[24]. - The total assets at the end of 2021 were RMB 2,825,602,235.14, reflecting a year-on-year increase of 16.90%[24]. - The net assets attributable to shareholders at the end of 2021 were RMB 1,561,213,992.01, up 18.55% from the previous year[24]. - Basic earnings per share (EPS) for 2021 was CNY 2.13, up 121.88% from CNY 0.96 in 2020[27]. - The weighted average return on equity (ROE) increased to 21.86%, up 10.13 percentage points from 11.73% in 2020[27]. - The company reported a quarterly revenue of CNY 672.16 million in Q4 2021, with a decline in net profit attributable to shareholders to CNY 67.64 million due to year-end impairment provisions[28]. Revenue Segmentation - Revenue from the pharmaceutical manufacturing segment grew by 43.92% year-on-year, while pharmaceutical commerce revenue increased by 24.48%[24]. - The pharmaceutical industry segment generated CNY 1,682.25 million in revenue, up from CNY 1,174.35 million in 2020[40]. - In 2021, the company achieved a 43.92% year-on-year growth in pharmaceutical industrial revenue, with OTC sales increasing by 51.28% and Rx sales growing by 36.23%[41]. - The company reported a decrease of 31.02% in revenue from other business segments[24]. - The pharmaceutical commercial segment reached 1,588.1850 million RMB, growing by 24.48%[59]. Product Development and R&D - The company initiated 25 new drug research projects in 2021, including 5 pediatric formulations, and received 1 new drug certificate[45]. - The company launched new products such as "Zhuo Bei Gao" children's growth milk powder and expanded its e-commerce business[45]. - The company has 39 ongoing research projects, including 25 new drug development projects, 10 secondary development projects, and 4 health food projects[110]. - The company is committed to enhancing its R&D capabilities and expanding its product pipeline in the future[119]. - The company plans to increase R&D investment and improve the conversion rate of research outcomes in response to the rapid inclusion of innovative drugs in the medical insurance system[54]. Market Strategy and Expansion - The company plans to focus on product development and marketing strategies to enhance competitiveness in response to industry changes[39]. - The company aims to maintain rapid growth in operating performance and asset quality through refined management and cost control[39]. - The company aims to enhance its position in the national supply chain by focusing on talent development and core technology breakthroughs, addressing critical issues in the pharmaceutical industry[49]. - The company is committed to high-quality innovation and increasing R&D investment in response to national policies encouraging innovation and high-end manufacturing[49]. - The company is actively exploring innovative business models, including traditional Chinese medicine services and health tourism[143]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[9]. - The company faces risks related to product concentration, with three key products accounting for over 50% of industrial revenue, necessitating a focus on product diversification[144]. - The company faces risks from fluctuations in raw material prices, particularly traditional Chinese medicine materials, which are affected by natural conditions and market supply-demand dynamics[147]. - The implementation of centralized procurement for traditional Chinese medicine by the National Medical Insurance Administration in 2022 poses a risk of product price declines[147]. - New drug development involves high investment and risk, with potential challenges in clinical efficacy and market acceptance[147]. Corporate Governance and Management - The company held 6 shareholder meetings and 15 board meetings, reviewing a total of 84 proposals[151]. - The company disclosed 146 pieces of information in 2021, including 4 regular reports and 77 temporary announcements, achieving a B rating from the Shanghai Stock Exchange for information disclosure[154]. - The company has established a management system for insider information, ensuring compliance and confidentiality[154]. - The company maintains open communication with investors through various channels, enhancing investor relations management[154]. - The total pre-tax remuneration for the chairman, He Qin, was CNY 1.0136 million, with a significant increase in shareholding from 0 to 318,720 shares due to equity incentives[162]. Future Outlook - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues of $1.32 billion[167]. - The company plans to invest $50 million in new technology to improve operational efficiency over the next two years[167]. - The company anticipates significant growth in the domestic pharmaceutical market due to increasing healthcare awareness and an aging population[139]. - The company plans to enhance market forecasting and strategic procurement to mitigate raw material supply risks[147]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[171].